Last updated on September 2018

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Brief description of study

Some HER-2 breast cancer patients do not respond or build resistance to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. This might improve outcomes for these patients.

Clinical Study Identifier: NCT03248492

Contact Investigators or Research Sites near you

Start Over

Principal Investigator

Royal Surrey County Hospital
Guildford, United Kingdom